Trial Parameters
Condition Lymphoma
Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-10-26
Completion 2028-10
All Conditions
Interventions
Whole Body-Magnetic Resonance Imaging (WB-MRI)
Brief Summary
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.
Eligibility Criteria
Inclusion Criteria: * Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above. * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged ≥ 18 years. * Life expectancy greater than 3 months. Exclusion Criteria: * Patients with MRI-unsafe prostheses and devices. * Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.
Related Trials
NCT06137144
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refra
View Trial →
NCT04739813
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR
View Trial →
NCT07305337
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
View Trial →